Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western hemisphere. It is characterized by a clonal accumulation of small, mature-looking lymphocytes in the blood, marrow and secondary lymphoid tissues. 1 The disease presents a highly variable clinical course, with some patients surviving for many years without requiring treatment and others who witness a rapidly progressing disease, associated with a short life expectancy, despite aggressive treatment.
Several biological and genetic properties of the leukemic cells, such as the mutational status of the immunoglobulin heavy chain variable genes (IGHV), 2 chromosome aberrations, 3 CD38 and ZAP-70 expression, 4,5 and p53 dysfunction 6 bear an important prognostic value and have enabled to stratify patients into risk categories. These parameters are in fact important independent predictors of disease progression and survival.
The deletion of chromosome 11q22-q23, that occurs in 10-20% of cases, 3 represents the second most common genetic abnormality in CLL and defines a subgroup of patients characterized by progressive disease and an overall unfavorable prognostic likelihood; 7 in fact, leukemic cells show increased survival rates, possibly due to inhibited apoptosis and to alterations of the genes involved in cell-cycle control and cell survival. 8 The ATM (ataxia-telangiectasia mutated) gene maps to chromosome 11q22-q23 within the minimal region of loss described in CLL 9 and several data indicate that the 11q deletion results in ATM gene inactivation. 10 The ATM gene is a member of the phosphatidylinositol-3 kinase (PT3K) family of genes and consists of 66 exons, of which 62 are coding exons.
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The ATM protein is a nuclear serine/threonine kinase of 350 kDa whose activities are DOI: 10.3324/haematol.2011.049270 induced by chromosomal double-strand breaks that arise endogenously or after exposure to DNA-damaging agents, including ionizing radiation (IR) and drugs. 12 The ATM protein is a pleiotropic molecule that protects the integrity of the genome by regulating the cell-cycle arrest at G1/S and G2/M to prevent processing of damaged DNA, and activating DNA-repair pathways and inducing apoptosis if the DNA damage cannot be repaired. 13 Many of these effects are mediated via a phosphatidylinositol-3 kinase domain in the C-terminus of the ATM protein (residues 2656-3056). The homozygosus mutation of the ATM gene is known to be the cause of ataxia-telangiectasia (A-T), an autosomal recessive disorder characterized by neurological and immunological symptoms, radiosensitivity and predisposition to cancer, particularly of the lymphoid system. 14 Several epidemiological studies suggest that the frequency of the A-T heterozygous carriers ranges between 0.5% and 1% in different countries; these individuals have a significantly increased risk of developing breast cancer 15 and CLL. 16, 17 One third of CLL patients have an inactive ATM and exhibit defects in the p53 damage response and in IR-induced apoptosis. 18, 19 These findings have considerable clinical implications because ATM mutations may be important in predicting potential treatment failures.
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In the present study we examined the mutational status of the ATM gene in a series of CLL patients studied at diagnosis. A multiplex gene dosage analysis of the ATM gene was also performed by MLPA. The results were then correlated with the known biological prognostic factors, including coexisting cytogenetic abnormalities, IGHV status genes, CD38 and ZAP-70 expression, TP53 mutations, as well as with gene expression profile.
Modeling structural analysis of the mutated ATM protein was carried out in order to understand the effects of the mutation on the behavior of the neoplastic cells. Table S1 .
All samples were analyzed for CD38 and ZAP-70 expression, for the IGHV status and for TP53 mutations as previously described.
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This study was approved by the Institutional Review Board of the Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome. All patients and controls gave their informed consent to blood collection and to the biologic analyses included in the present study according to the Declaration of Helsinki.
DNA was extracted from the leukemic cells of the 57 unrelated patients and tumor DNA was analyzed to determine ATM mutations. The detected ATM alterations were investigated in patient-matched buccal cells DNA to determine their germline or somatic nature.
DHPLC analysis of ATM gene
Mutation scanning was performed by DHPLC analysis, following previously published protocols 22, 23 in which a 86% mutation detection rate in ATM mutated patients and a 100% specificity has been reported.
Sixty-two out of the 66 exons of ATM, along with exon-intron junctions, were PCRamplified. 22 Denaturing High Performance Liquid Chromatography (DHPLC) analysis followed previously published protocols. 22, 23 All amplification products showing an abnormal elution profile were re-amplified and sequenced in the forward and reverse direction using the BigDye Terminator chemistry and an ABI PRISM 3100 automated DNA sequencer (Applied Biosystems). The pathogenic role of novel missense and intronic changes was evaluated by screening 360 control chromosomes from 180 unrelated healthy individuals.
MLPA analysis of ATM gene
To estimate the contribution of single and multi-exon ATM gene copy-number changes, that could be missed with large FISH probes, a MLPA analysis was performed using the SALSA MLPA kit P123 ATM, available from MRC Holland (MRC-Holland, Amsterdam, The Netherlands).
This assay consists of two reaction mixes containing probes for 33 of the 66 constitutive ATM exons and control probes for sequences located in other genes. An aliquot of 150 ng of denatured genomic DNA was used in the overnight annealing of the exon-specific probes and subsequent ligation reaction. PCR was performed with FAM-labelled primers using 10 ml of ligation reaction. Separation and quantification of the amplification products were carried out using an ABI Prism 3130 Genetic Analyzer (Applied Biosystem 
Statistical analysis of TFI
TFI was calculated from the date of diagnosis to first treatment. The probability of TFI was estimated using the Kaplan-Meier test; since no patient died before treatment, it was not necessary to estimate TFI by means of cumulative incidence curves, considering death before treatment as a competing risk. The Log-rank test was used to test differences between groups.
RNA extraction and oligonucleotide microarray
Total RNA was extracted using the RNeasy mini procedure (Qiagen), according to the manufacturer's instructions with minor modifications. All samples analyzed contained at least 90% leukemic cells. HGU133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA) were used to determine gene expression profiles. Briefly, first strand cDNA was synthesized from 5 ! g total RNA using T7-(dT) 24 primers and reverse transcribed with the Roche Applied Science Microarray cDNA Synthesis kit (Mannheim, Germany); after the second strand cDNA synthesis, the product was used in an in vitro transcription reaction (Roche Applied Science Microarray RNA Target Synthesis (T7) kit) to generate biotinylated complementary RNA (cRNA). Eleven ! g of fragmented cRNA were hybridized on microarrays for 16 hours and subsequently gene chips were washed, stained and scanned.
Statistical methods for microarray analysis
Oligonucleotide microarray analysis was performed with the dChip software (www.dchip.org), which uses an invariant set normalization method where the array with median overall intensity was chosen as the baseline for normalization. Model based expressions were computed for each array and probe set using the PM-MM model.
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Non-specific filtering criteria for unsupervised clustering required the expression level to be higher than 300 in >10% of the samples and the ratio of the standard deviation (SD) to the mean expression across all samples to be between 1 and 1,000. Unsupervised clustering was performed as described by Eisen et al.
25
To identify genes differentially expressed between different CLL subclasses, a t-test was applied: probe-sets were required to have an average expression >100 in at least one group, a p-value <0.05 and a fold change >1.5. Identification of gene functional annotation was performed using the DAVID database (http://david.abcc.ncifcrf.gov).
Real-time quantitative PCR analysis
One µg of total RNA was retro-transcribed using the Advantage RT-for-PCR Kit (Clontech, Primers were designed by Primer Express 1.5.1 software (Applied Biosystems). Gene symbols and primers are listed in the online Supplemental Table S2 .
Box plots and p-values were obtained using a tool available on the website (http://www.physics.csbsju.edu/stats/).
Molecular modeling of the ATM kinase domain
The structure of the PI3K-like domain of ATM in the amino acid (a.a.) interval 2623-2953 was built by homology modeling using the program MODELLER (release 9v3) 26 and using as a template the structure of the homologous porcine PI3K" in complex with ATP (Protein Data Bank, PDB, entry 1E8X), according to alignment of sequence and secondary structure elements (the latter are predicted by PSIPRED for ATM and experimental for porcine PI3K"), as shown in online Supplemental Figure S1 . To assess the congruence of the proposed architectural model, we have also verified whether a.a. crucial for kinase activity are properly located inside the structure.
Specifically, we have identified the position of the lysine that interacts with the phosphate group of ATP and the aspartic acid that acts as proton acceptor, which are the two active site residues directly involved in kinase activity. The first of these two residues in ATM appears to be the invariant Lys2717, because it aligns accurately with Lys833 of porcine PI3K", which in turn is known as the active site lysine for this homologous kinase. 27 The proton acceptor residue in ATM turns out to be the invariant Asp2870 owing to its geometric coincidence with the annotated catalytic aspartic acid residue of another structurally characterized kinase (PDB structure 1VYW, cell division protein kinase 2) that is observed after rigid superposition of this latter structure with our model.
Results

DHPLC analysis for ATM mutations
Fifty seven CLL patients were screened for mutations in the 62 coding exons of the ATM gene. Mutational screening of the ATM gene identified 8 (14%) patients with heterozygous mutations: 1 frameshift 2502insA, 1 splicing mutation IVS29+5G>A, 6 missense, 8095C>T
(P2699S), 8071C>T (R2691C), 2476A>C (I826L) and 1435G>T (D479Y) in 3 patients:
given the relatively high incidence of the latter mutation, in order to exclude the possibility of a contamination, the presence of this mutation was screened, and confirmed in two different DNA aliquots from the same individual (Table 1 ). In 4/8 cases, the ATM mutations have also been tested on the non-neoplastic cell population, namely buccal cells, to verify whether the alteration was germline or carried only by the neoplastic cells: in 1/4 cases the mutation was germline (Table 1 ).
In addition, 9 different variants or polymorphisms, defined on the basis of referenced data, were found in 14 patients (online Supplemental Table S3 ); their functional significance is unknown. ATM mutations, variants and polymorphisms have been also evaluated in 180
healthy volunteers, to test in matched controls if these variants segregate in the Italian population and to verify their frequency (online Supplemental Table S3 ).
MLPA analysis for ATM deletions/duplications
All 57 CLL patients were analyzed for ATM gene copy number variations by MLPA. This 
Relationship between ATM gene mutations and prognostic factors
Patients with ATM point mutations
Analysis of the sequence of IGHV genes in the 8 ATM-mutated cases showed in 6 an unmutated status and in 2 (MR 3664; AE 5646) a mutated status ( At the time of data analysis, 6/8 of patients with ATM mutation had undergone treatment (MR 3664; PD 3988; GF 3706; ID 5637; CG 5116) and the median TFI was 30.0 months.
Patients with ATM deletions
All cases showing a significant reduction of ATM gene expression, evaluated by MLPA analysis, had a proportion of 11q23 deleted cells greater than 20% (Table 2) . One case showed a concomitant 17p13 deletion in 7% of the leukemic cells. At the time of data analysis, all 11q23 deleted patients had been treated and the median TFI was 23.5 months.
Patients without ATM mutations or deletions
Forty-three of the 57 CLL analyzed showed no ATM gene mutation or 11q23 deletion (Table 2) . Two patients disclosed del17p13, but only 1 in more than 20% of the leukemic cells, and 1 patient had a TP53 gene mutation. 
Microarray analysis in CLL cells with ATM point mutations
To evaluate the effects of ATM mutations on CLL cells, we performed a gene expression profile analysis on 41 of the 57 CLL patients characterized for the ATM mutational status.
We first utilized an unsupervised approach applying non-specific filtering criteria:
hierarchical clustering based on a list of 226 selected genes showed that 3/5 ATM-mutated cases were included in the same cluster of patients; of note, two samples harbored the same ATM mutation (1435G>T) (data not shown).
Subsequently, we performed a supervised analysis comparing the ATM-mutated cases with the remaining CLL samples; as shown in Figure 2A , this approach revealed a Figure 2B ).
Microarray analysis in CLL cells with ATM deletions
The unsupervised analysis on CLL samples highlighted that 4/6 MLPA+ patients were included in the cluster with ATM-mutated samples mentioned above (data not shown).
We subsequently performed a supervised analysis using a t-test between MLPA+ cases and the other CLL samples, independent of ATM mutations ( Figure 3A ). This comparison identified 98 differentially expressed genes, as reported in the online Supplemental In line with these findings, the decrease of expression levels of this set of genes correlated with the percentage of cells carrying the deletion ( Figure 3B ).
Furthermore, as already done for ATM mutations, in order to exclude the effects of IGHV mutational status, the same analysis was performed exclusively on CLL IGHV unmutated samples, achieving analogous results (data not shown).
Validation of gene expression data by Q-PCR analysis
To Figure 2B ).
Furthermore, we also evaluated the expression of a set of transcripts commonly deregulated in CLL with ATM alterations. In agreement with the gene expression data, BACE2 and TMPRSS6 were significantly down-regulated in both ATM-mutated and deleted patients, whereas PCDH9 and RXRA were modulated in the opposite way in these two subclasses compared to the other CLL (online Supplemental Figure 2C ).
Finally, when we extended the analysis to an additional cohort of cases, including ù 5 CLL with ATM point mutations and 5 CLL with del11q, comparable results were obtained (data not shown).
ATM protein mutations modeling
Mutation D479Y was analyzed since it was detected in 3 ATM-mutated cases ( Table 1 ).
The understanding of the implications of this a.a. change on ATM function was difficult, since this region of the protein has so far not been studied. D479Y is included in the $ -helix formed by a.a. 478-494 (secondary structure prediction by PSIPRED) and shows a high conservation across species having as a much less frequent alternative only glutammic acid, which is also a negatively charged residue. These features suggest the importance of this residue.
To understand the effects of the R2691C and P2699S mutations, we have built the structure of the PI3K-like domain of ATM by homology modeling. The match between the pattern of secondary structures of ATM kinase and PI3K" (online Supplemental Figure S1 )
allows an unambiguous localization of the sites of R2691C and P2699S mutations in the pocket that binds the ATP co-factor ( Figure 4 ). The R2691C mutation implies the replacement of a large and positively charged arginine with the small and neutral cysteine residue, introducing significant structural and electrostatic changes in the ATP binding pocket. As for the P2699S mutation, according to the alignment and predicted secondary structure, the presence of a proline at position 2699 suggests that this residue acts as a breaker of the %-sheet formed by a.a. 2700-2706 (proline residues are commonly found as $-helix and %-sheet disruptor), thus initiating the formation of a reverse turn that is followed N-terminally by another %-sheet (a.a. 2690-2693). Such secondary structure arrangement is essential for kinases and it is likely to be lost with the P2699S mutation in which the invariant proline is replaced by a serine.
Owing to such important effects in a region critical for the binding of the co-factor, R2691C
and P2699S mutations are each expected to impair the kinase activity of ATM.
I826L modeling was not evaluated since the mutation falls outside the PI3K-like domain. The majority of patients with ATM mutations showed poor prognostic biologic features: an IGHV unmutated status, ZAP-70 and CD38 expression. 32 Altogether, these parameters correlate with the clinical behavior of the disease; in fact, the majority of patients carrying ATM mutations required treatment for disease progression over a short observation time:
DISCUSSION
100% of deleted ATM patients required therapy within a median of 23.5 months and 62.5%
of patients with ATM point mutations needed treatment within a median of 30.0 months after diagnosis. Overall, the TFI of CLL patients with ATM alterations was significantly shorter compared to that of patients not harboring such abnormalities (64.2 months).
These findings extend previously published data. 7, 20, 30 In an attempt to explain this The peculiar gene expression profile of ATM-mutated and deleted patients was confirmed when the analysis was restricted to IGHV unmutated cases, suggesting that ATM gene alterations induce a peculiar gene expression profile in itself.
Our results suggest that both deletions and mutations of the ATM gene peculiarly affect gene expression profile. However, the genes involved are different in the two groups, with only a small set of 4 genes commonly deregulated in both mutated and deleted CLL patients. These results suggest that, at the biological level, different mechanisms might be involved in the impairment of the ATM pathway, but provide a similar adverse clinical effect. 
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Two patients carrying the Asp479Tyr mutation fell in the same cluster of gene expression profile suggesting that the mutation could play a role in the behavior of the leukemic cells.
The PI3K-like domain of ATM built by homology modeling allows to locate the sites of R2691C and P2699S mutations in the pocket that binds the ATP co-factor ( Figure 4B ).
This region shows a high vulnerability to mutations since it is directly involved in the interaction with the co-factor. The important changes associated with each of the two mutations modify critically this part of the structure impairing ATM kinase activity.
Important biological consequences can be envisioned for R2691C and P2699S mutants. 
